Biblio
Export 417 results:
Author Title [ Type
Filters: First Letter Of Keyword is S [Clear All Filters]
“Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
, “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
, “Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 195-208, 2018.
, “Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 195-208, 2018.
, “Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 179-95, 2016.
, “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1033-43, 2016.
, “Digital Technologies to Prevent Social Isolation and Loneliness in Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 90, no. 2, pp. 513-528, 2022.
, “Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.”, Cell, vol. 146, no. 3, pp. 359-71, 2011.
, “Distinct Patterns of Cognitive Aging Modified by Education Level and Gender among Adults with Limited or No Formal Education: A Normative Study of the Mini-Mental State Examination.”, J Alzheimers Dis, vol. 49, no. 4, pp. 961-9, 2016.
, “Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.”, Proc Natl Acad Sci U S A, vol. 107, no. 28, pp. 12698-703, 2010.
, “Divergent Longitudinal Propagation of White Matter Degradation in Logopenic and Semantic Variants of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 49, no. 3, pp. 853-61, 2016.
, “Diversity of Cognitive Phenotypes Associated with C9ORF72 Hexanucleotide Expansion.”, J Alzheimers Dis, vol. 52, no. 1, pp. 25-31, 2016.
, “Do Microglia Default on Network Maintenance in Alzheimer's Disease?”, J Alzheimers Dis, vol. 51, no. 3, pp. 657-69, 2016.
, “Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?”, J Alzheimers Dis, vol. 61, no. 2, pp. 515-519, 2018.
, “Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?”, J Alzheimers Dis, vol. 51, no. 4, pp. 1275-89, 2016.
, “Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.”, J Alzheimers Dis, vol. 52, no. 2, pp. 433-49, 2016.
, “Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers.”, J Alzheimers Dis, vol. 52, no. 2, pp. 433-49, 2016.
, “Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of Aβ 1-42.”, J Alzheimers Dis, vol. 50, no. 2, pp. 501-16, 2016.
, “Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of Aβ 1-42.”, J Alzheimers Dis, vol. 50, no. 2, pp. 501-16, 2016.
, “Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of Aβ 1-42.”, J Alzheimers Dis, vol. 50, no. 2, pp. 501-16, 2016.
, “Early and Persistent O-GlcNAc Protein Modification in the Streptozotocin Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 237-249, 2018.
, “Early and Persistent O-GlcNAc Protein Modification in the Streptozotocin Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 237-249, 2018.
,